Introduction
The rising morbidity and mortality of cancer has drawn extensive attention worldwide, and finding possible risk factors of tumorigenesis has been a priority task for researchers. Recently, an increasing number of studies have focused on associations between miRNA polymorphisms and cancer susceptibility, which indicated that accumulation of genetic variants may be involved in cancer development, including oral cancer, 1 lung cancer, 2,3 gastric cancer, 4 breast cancer, 5 glioma, 6 non-small cell lung cancer, 7 hepatocellular carcinoma, 8, 9 gallbladder cancer, 10 and head and neck cancer (HNC). 11 As the molecular mechanism of cancer remains unclear, further exploration of more accurate cancer treatments and prognosis would be of great importance.
MiRNAs are a class of small non-coding RNAs with 18-25 nucleotides in length, which play as oncogenes or anti-oncogenes in the pathogenesis of tumor by targeting multiple genes. [12] [13] [14] Studies have shown that almost 10%-30% of all human gene expressions have been regulated by mature miRNAs. 15 MiRNAs could modulate related genes implicated in cellular processes, including cell differentiation, growth, apoptosis, and immune response. polymorphisms (SNPs) provide new sources of genetic variation, which contribute to potential molecular mechanisms of cancer development. 22 SNPs or mutations in miRNA sequence may transform miRNA expression and/or maturation, related to miRNA function by activating the transcription of the primary transcript, pri-miRNA and pre-miRNA processing, and miRNA-mRNA interactions. 23 MiR-196a2 rs11614913, as a definitional miRNA polymorphism, [24] [25] [26] is crucially associated with cancer risk. 23, 27 It is located in the 3′-untranslated region of the miR-196a2 precursor. 28 Hoffman et al 5 also showed that miR-196a2 rs11614913 not only influenced the transcription level of mature miR-196a, but also had a biological effect on target gene production. This updated meta-analysis was performed to explore the association between the hsa-miR-196a2 polymorphism and cancer risk and to further estimate the overall cancer risk by pooling all available data.
Materials and methods

Publication search
Two investigators (LYH, HAB) carried out a systematic review on PubMed, Cochrane Library, and Web of Science, by using ("microRNA-196a2" or "miR-196a2", or "miR-196-a-2" or "miR-196-2" or "miR-196-a" or "rs11614913"), and ("cancer" or "tumor" or "carcinoma" or "neoplasm" or "malignancy"), and ("polymorphism" or "variation" or "susceptibility") as the search terms in order to identify potentially eligible studies. We based our dates for literature retrieval from January 2008 to September 2017.
inclusion and exclusion criteria
Relevant studies had to meet the following inclusion criteria: 1) full-text article; 2) evaluation of a link between miRNA polymorphisms and cancer risks; 3) sufficient data for estimating the odds ratio (OR) with 95% CI and a P-value. Studies containing two or more case-control groups were considered as two or more independent studies. Studies that were, 1) review, letters, and comment articles; 2) not for cancer risk; and 3) duplicate samples or publications, were excluded.
Assessment of study quality
The quality of the study was determined by the NewcastleOttawa Scale for cohort studies.
Data extraction
Data extraction from the eligible studies were performed independently by two authors (LYH, HAB), based on the inclusion and exclusion criteria. For each publication, the following data were recorded: first author, date of publication, country of origin, ethnicity, type of tumor, source of control groups, total numbers of cases and controls, and genotyping method.
Statistical analysis
The departure of frequencies of miR-196a2 rs11614913 polymorphisms was assessed under the Hardy-Weinberg equilibrium (HWE) for each publication by adopting the goodness-of-fit test (chi-square or Fisher exact test). The association between the miR-196a2 rs11614913 polymorphisms and the risk of cancer was evaluated by calculating pooled OR together with corresponding 95% CI based on the method published by Woolf. 29 Also, a P-value,0.05 was considered statistically significant. In addition, we used stratified metaregression analyses to explore major causes of heterogeneity among the articles. We respectively examined the association between genetic mutants and cancer risk in allelic contrast (T vs C), homozygote comparisons (TT vs CC), heterozygote comparisons (TC vs CC), recessive model (TT vs TC+CC), and dominant model (TT+TC vs CC). Subgroup analyses were performed by ethnicity (Asian and Caucasian), tumor types (if one tumor type contained less than three individual studies, it was combined into "other cancer" subgroups), and source of control (hospital based and population based).
Q tests 30 and I² tests 31 were carried out to test the heterogeneity. I² values describe the percentage of total variation across studies that are due to heterogeneity rather than chance. I²=0% prompts no heterogeneity observed, with 25% identified as low, 50% as moderate, and 75% as high. If I² was $50% or if the P-value of heterogeneity was ,0.05, indicating significant heterogeneity among these articles, a randomeffect model was used; 32 otherwise, a fixed-effect mode was used. 33 Sensitivity analyses were conducted to estimate the stability of the meta-analysis result. We adopted Egger's test to assess potential publication bias by visual inspection of the Funnel plot. A P-value ,0.05 was regarded as an indication of potential publication bias. 34 All statistical analyses were performed with the Stata software package version 12.0 (Stata Corporation, College Station, TX, USA).
were subjected to further checking. In the present metaanalysis, we excluded 73 articles (36 articles were metaanalysis, 22 articles did not express concern about cancer risk, 11 articles lacked detailed allele frequency data or OR calculation, and four articles were incomplete text). The included study characteristics are provided in Table 1 .
In total, there were studies on hepatocellular carcinoma (n=14), breast cancer (n=14), colorectal cancer (n=10), gastric cancer (n=10), lung cancer (n=9), esophageal squamous cell carcinoma (ESCC; n=6), HNC (n=5), bladder cancer (n=2), prostate cancer (n=2), oral squamous cell carcinoma (n=2), epithelial ovarian cancer (n=2), renal cell cancer (n=1), glioma (n=1), pancreatic cancer (n=1), cervical cancer (n=1), nasopharyngeal carcinoma (n=1), gallbladder cancer (n=1), acute lymphoblastic leukemia (n=1), and nonHodgkin lymphoma (n=1). There were 64 studies of Asians and 18 studies of Caucasians.
Among the genotyping methods used in these studies, 57 studies used polymerase chain reaction (including polymerase chain reaction restriction fragment length polymorphism and polymerase chain reaction-ligation detection reaction), 16 studies used Taqman SNP genotyping assay, and others used MassARRAY and DNA sequencing. The controls of 42 studies mainly came from a hospital-based healthy population matched for gender and age, and 42 studies had population-based controls (PB). The distribution of genotypes in the controls of all of the studies was in agreement with HWE (P.0.05).
Quantitative synthesis
In this meta-analysis, we analyzed the hsa-miR-196a2 rs11614913 polymorphism in 84 comparisons with 35,802 cases and 41,541 controls. All the studies were pooled into the meta-analysis, and the results showed that the hsa-miR196a2 rs11614913 polymorphism was significantly associated with the risk of cancer in the following genetic models: TT vs CC: OR =0.900, 95% CI =0.813-0.987, P=0.043; TT vs TC+CC: OR =0.918, 95% CI =0.851-0.989, P=0.025.
Then, we performed the subgroup analysis of different specific cancer types, genotypes, control sources, and ethnicities ( 
Test of heterogeneity
Among the studies of rs11614913, we found heterogeneity in overall comparisons and subgroup analysis. Moreover, the heterogeneity we evaluated for all genetic models by ethnicity, cancer type, source of controls, as well HWE status was significant. However, we found that heterogeneity could not be explained by the variable ethnicity, cancer type, source of controls, and HWE status (data not shown).
Sensitivity analysis
Sensitivity analysis was conducted to assess the effect by excluding a single study in turn. Sensitivity analysis of the rs11614913 polymorphism in an allelic comparison is presented in Table S1 . Overall, we found that no individual study had an influence on the pooled OR. The results demonstrated that the pooled ORs were not materially altered, suggesting the stability of our meta-analysis.
Publication bias
The publication bias of the present meta-analysis was assessed by Begg's funnel plot and Egger's test. The funnel plot for the rs11614913 polymorphism in the allelic comparison is presented Table 3 .
Discussion
MiRNAs are reported as critical posttranscriptional regulators in gene expression and are involved in various diseases.
The associations between miR-196a2 rs11614913 polymorphism and susceptibility to different cancers are widely explored. Guo et al 101 found that the C allele had the effect of increasing cancer risk in gastric cancer, and Ma et al 102 found that TT could decrease the risk of colorectal cancer. Moreover, Wang et al 103 and Zhang et al 104 showed that the rs11614913 polymorphism has no association with the risk of hepatocellular carcinoma. However, the regulatory effects of miRNA in carcinogenesis remain unclear. Therefore, we performed this updated meta-analysis to explore the molecular mechanisms of the genetic associations between miRNA and SNPs with cancer risk.
MiR-196a2 is composed of two distinct mature miRNAs (miR-196a-3P and miR-196a-5P), which are processed from the same stem loop; 105 thus, the potential targets of miR-196a could be influenced by its altered expression patterns. SNPs in miRNAs could potentially affect the processing or target selection of miRNAs, 106, 107 which is identified as a key factor in oncogenesis, and contributes to regulate the translation or degradation of messenger RNA (mRNA). 23 Hoffman et al 5 found that the expression of mature miR-196a2 was increased 9.3-fold in cells transfected with pre-miR-196a2-C but upregulated only by 4.4-fold with pre-miR-196a2-T, and that the C allele of rs11614913 increased mature miR-196a2 levels in lung cancer 7 (lower cycle threshold corresponding to a higher expression) in cardiac tissue specimens of congenital heart disease, and the increased miR-196a expression could further decrease mRNA target of HOXB8. These results indicated that the rs11614913 polymorphism may affect the processing of the pre-miRNA to its mature form.
Several meta-analyses have been performed to analyse the SNP of this miRNA that is associated with the cancer risk. 104, 109 In our present work, we screened out all the studies published to date and included more papers and cancer types than the previously published meta-analyses. For example, Kang et al 109 conducted a meta-analysis encompassing the rs11614913 polymorphism in miR-196a2 and cancer risks, which suggested that the rs11614913 polymorphism may contribute to decreased susceptibility to liver cancer (allele model, homozygous model, dominant model, and heterozygous model) and lung cancer (allele model, homozygous model, and recessive model); however, this was not duplicated in our meta-analysis. In this study, we concluded that the rs11614913 polymorphism conferred a decreased susceptibility to lung cancer (homozygote comparison, recessive model) and hepatocellular carcinoma (allelic contrast, homozygote comparison, recessive model) or an increased susceptibility to HNC (allelic contrast, homozygote comparison). Our study had a larger sample size than the previous ones, which might influence the results. In addition, the previous meta-analyses did not evaluate the quality of the included studies.
According to the procedure of seeking for the source of heterogeneity, we performed subgroup studies according to cancer type, ethnicity, and source of control. A strong association was found between rs11614913 and cancer risk in lung cancers, hepatocellular carcinoma, and HNC, but not in breast cancer, gastric cancer, ESCC, or CRC, which was not similar to the findings of previous studies. [101] [102] [103] 109 The present meta-analysis showed that homozygote TT had the effect of decreasing the risk of lung cancer or hepatocellular carcinoma compared with that of CC homozygote or C allele carriers. We conducted another subgroup analysis by population to determine the association between these miRNA polymorphisms and tumorigenesis. The results suggested that individuals with alterative T allele could decrease cancer susceptibility in Asians but not in Caucasians, indicating that the difference of ethnic background and the living environment may also be a risk factor.
To determine the hsa-miR-196a2 rs11614913 polymorphism, PCR, Taqman, and other methods have been adopted. We found that the hsa-miR-196a2 rs11614913 polymorphism significantly decreased cancer risk in homozygous models and the recessive model when using the PCR method, but this result was not shown when selecting Taqman and other methods. Therefore, more effort may be necessary for further progress in SNP analysis. We found sources of heterogeneity in the studies from cancer type and ethnicity suggesting cancer and population playing important roles. When detecting the source of control, we observed significant associations in population-based and hospital-based controls. This may be due to the included studies matching age, gender, and residential area to control selection bias. 
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Liu et al Nevertheless, several defects of this meta-analysis should be emphasized. Firstly, although we strictly screened articles and precisely extracted the data, the differences in the selection of subjects could not be eliminated. Secondly, in our meta-analysis, only Asian and Caucasian ethnicities were included, and the impact of the differences in racial descent should not be ignored. Thirdly, potential language bias could not be avoided due to limitation of studies published in English or Chinese. Therefore, it is not possible to avoid potential publication bias in this meta-analysis.
In summary, miR-196a2 rs11614913 polymorphism may contribute to the development of cancer, especially in lung cancer, hepatocellular carcinoma, and HNC. It might be useful as a candidate marker for the diagnosis of these cancers, and could also be a potential protective factor for cancer risks in Asians. Furthermore, more significant studies and investigations with larger populations focusing on cancer types or ethnicities should be performed to confirm the results. 
